Evidence map›Paper›PMID 29603739›Full record

ArticleThe Journal of pathology2018

Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules.

Bo He, Arnaud Jabouille, Veronica Steri, Anna Johansson-Percival, Iacovos P Michael, Venkata Ramana Kotamraju, Reimar Junckerstorff, Anna K Nowak, Juliana Hamzah, Gabriel Lee and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 3 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 3 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Linking tumour angiogenesis and tumour immunity.Nature reviews. Immunology · 2026
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Cell-Based Therapies for Solid Tumors: Challenges and Advances.International journal of molecular sciences · 2025
    Review
  19. Tertiary Lymphoid Structures in Central Nervous System Disorders.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Bo HeThe Harry Perkins Institute of Medical Research, Centre for Medical Research, University of Western Australia, Nedlands, Australia.
Arnaud JabouilleDepartment of Neurological Surgery, Brain Tumour Research Center, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Veronica SteriDepartment of Neurological Surgery, Brain Tumour Research Center, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Anna Johansson-PercivalThe Harry Perkins Institute of Medical Research, Centre for Medical Research, University of Western Australia, Nedlands, Australia.
Iacovos P MichaelSwiss Institute for Experimental Cancer Research, School of Life Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne, Switzerland.
Venkata Ramana KotamrajuCancer Research Center, Sanford Burnham Prebys Medical Research Institute, La Jolla, CA, USA.
Reimar JunckerstorffSchool of Pathology and Laboratory Medicine, University of Western Australia, Nedlands, Australia.
Anna K NowakSchool of Medicine, University of Western Australia, Nedlands, Australia.
Juliana HamzahThe Harry Perkins Institute of Medical Research, Centre for Medical Research, University of Western Australia, Nedlands, Australia.
Gabriel LeeSchool of Surgery, University of Western Australia, Nedlands, Australia.
Gabriele BergersDepartment of Neurological Surgery, Brain Tumour Research Center, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Ruth GanssThe Harry Perkins Institute of Medical Research, Centre for Medical Research, University of Western Australia, Nedlands, Australia.ORCID 0000-0002-5551-045X
The University of Western Australia · AUUniversity of California, San Francisco · USÉcole Polytechnique Fédérale de Lausanne · CHSanford Burnham Prebys Medical Discovery Institute · USSt John of God Subiaco Hospital · AU

Funding

Autophagy as a microenvironmental regulator of tumorigenesis and resistanceR01CA188404 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGERS, GABRIELE, DEBNATH, JAYANTA · 2014 to 2018
$2.1M
Inter-regulatory function of immune-modulation and angiogenesis in cancerR01CA201537 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BERGERS, GABRIELE · 2016 to 2020
$1.7M
NCI NIH HHS R01 CA188404NCI NIH HHS R01 CA201537
6 · The paper itself

Abstract

High-grade brain cancer such as glioblastoma (GBM) remains an incurable disease. A common feature of GBM is the angiogenic vasculature, which can be targeted with selected peptides for payload delivery. We assessed the ability of micelle-tagged, vascular homing peptides RGR, CGKRK and NGR to specifically bind to blood vessels in syngeneic orthotopic GBM models. By using the peptide CGKRK to deliver the tumour necrosis factor (TNF) superfamily member LIGHT (also known as TNF superfamily member 14; TNFSF14) to angiogenic tumour vessels, we have generated a reagent that normalizes the brain cancer vasculature by inducing pericyte contractility and re-establishing endothelial barrier integrity. LIGHT-mediated vascular remodelling also activates endothelia and induces intratumoural high endothelial venules (HEVs), which are specialized blood vessels for lymphocyte infiltration. Combining CGKRK-LIGHT with anti-vascular endothelial growth factor and checkpoint blockade amplified HEV frequency and T-cell accumulation in GBM, which is often sparsely infiltrated by immune effector cells, and reduced tumour burden. Furthermore, CGKRK and RGR peptides strongly bound to blood vessels in freshly resected human GBM, demonstrating shared peptide-binding activities in mouse and human primary brain tumour vessels. Thus, peptide-mediated LIGHT targeting is a highly translatable approach in primary brain cancer to reduce vascular leakiness and enhance immunotherapy. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Indexed as

Drug CarriersNeovascularization, PathologicAdultAgedAged, 80 and overAngiogenesis InhibitorsAnimalsBrain NeoplasmsCell LineCell-Penetrating PeptidesDrug CompoundingFemaleGlioblastomaHumansLymphocytesMaleAngiogenesis InhibitorsCell-Penetrating PeptidesDrug CarriersMicellesTnfsf14 protein, mouseTumor Necrosis Factor Ligand Superfamily Member 14angiogenesisglioblastomaimmunotherapyLIGHTTNFSF14vascular targeting

Identifiers

PMID29603739
PMCPMC6737176
OpenAlexW2794947378

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.